Zaidi Ghazala, Bhatia Vijayalakshmi, Sahoo Saroj K, Sarangi Aditya Narayan, Bharti Niharika, Zhang Li, Yu Liping, Eriksson Daniel, Bensing Sophie, Kämpe Olle, Bharani Nisha, Yachha Surendra Kumar, Bhansali Anil, Sachan Alok, Jain Vandana, Shah Nalini, Aggarwal Rakesh, Aggarwal Amita, Srinivasan Muthuswamy, Agarwal Sarita, Bhatia Eesh
Departments of EndocrinologySanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
Departments of GastroenterologySanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
Endocr Connect. 2017 Jul;6(5):289-296. doi: 10.1530/EC-17-0022. Epub 2017 Apr 26.
Autoimmune polyendocrine syndrome type 1 (APS1) is a rare autosomal recessive disorder characterized by progressive organ-specific autoimmunity. There is scant information on APS1 in ethnic groups other than European Caucasians. We studied clinical aspects and autoimmune regulator () gene mutations in a cohort of Indian APS1 patients.
Twenty-three patients (19 families) from six referral centres in India, diagnosed between 1996 and 2016, were followed for [median (range)] 4 (0.2-19) years.
Clinical features, mortality, organ-specific autoantibodies and gene mutations were studied.
Patients varied widely in their age of presentation [3.5 (0.1-17) years] and number of clinical manifestations [5 (2-11)]. Despite genetic heterogeneity, the frequencies of the major APS1 components (mucocutaneous candidiasis: 96%; hypoparathyroidism: 91%; primary adrenal insufficiency: 55%) were similar to reports in European series. In contrast, primary hypothyroidism (23%) occurred more frequently and at an early age, while kerato-conjunctivitis, urticarial rash and autoimmune hepatitis were uncommon (9% each). Six (26%) patients died at a young age [5.8 (3-23) years] due to septicaemia, hepatic failure and adrenal/hypocalcaemic crisis from non-compliance/unexplained cause. Interferon-α and/or interleukin-22 antibodies were elevated in all 19 patients tested, including an asymptomatic infant. Eleven mutations were detected, the most common being p.C322fsX372 (haplotype frequency 37%). Four mutations were novel, while six others were previously described in European Caucasians.
Indian APS1 patients exhibited considerable genetic heterogeneity and had highly variable clinical features. While the frequency of major manifestations was similar to that of European Caucasians, other features showed significant differences. A high mortality at a young age was observed.
1型自身免疫性多内分泌腺综合征(APS1)是一种罕见的常染色体隐性疾病,其特征为进行性器官特异性自身免疫。除欧洲白种人外,其他种族中关于APS1的信息很少。我们研究了一组印度APS1患者的临床特征及自身免疫调节因子(AIRE)基因突变情况。
对1996年至2016年间来自印度6个转诊中心诊断的23例患者(19个家庭)进行了[中位数(范围)]4(0.2 - 19)年的随访。
研究临床特征、死亡率、器官特异性自身抗体及AIRE基因突变情况。
患者的发病年龄[3.5(0.1 - 17)岁]和临床表现数量[5(2 - 11)]差异很大。尽管存在遗传异质性,但APS1主要组成部分的发生率(黏膜皮肤念珠菌病:96%;甲状旁腺功能减退:91%;原发性肾上腺皮质功能减退:55%)与欧洲系列报道相似。相比之下,原发性甲状腺功能减退(23%)发生频率更高且发病年龄较早,而角膜结膜炎、荨麻疹皮疹和自身免疫性肝炎则不常见(各为9%)。6例(26%)患者在年轻时[5.8(3 - 23)岁]因败血症、肝衰竭以及因不依从/不明原因导致的肾上腺/低钙血症危象而死亡。在所有19例接受检测的患者中,包括1例无症状婴儿,干扰素-α和/或白细胞介素-22抗体均升高。检测到11种AIRE基因突变,最常见的是p.C322fsX372(单倍型频率37%)。4种突变是新发现的,另外6种突变先前在欧洲白种人中已有描述。
印度APS1患者表现出相当大的遗传异质性,临床特征高度可变。虽然主要表现的发生率与欧洲白种人相似,但其他特征存在显著差异。观察到年轻时死亡率较高。